SLC6A13

Across TCGA pan-cancer cohorts, SLC6A13 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC6A13 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC6A13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC6A13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LUSC, and UCEC are the cancer types where SLC6A13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.083	0.572	<.001	12	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
UCEC	DFS	Median	All	0.953	0.827	.019	8	view →
LGG	OS	Median	All	0.333	0.830	.012	6	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →
LIHC	OS	Median	All	0.164	0.707	.001	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC6A13–BLCA (DFS)

Open the BLCA breakdown →